The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia

To The Editor:The role of measurable residual disease(MRD)in prognosis and treatment in acute myeloid leukemia(AML)is evolving.Studies have demonstrated the correlation between MRD and risks of relapse in adult AML:persistently positive MRD after induction is associated with a high risk of relapse,1,2 and these patients should consider allogeneic transplantation(allo-Hematopoietic Stem Cell Transplantation(HSCT))and clinical trial,even in favorable-risk groups.However,because of the financial issue or lack of suitable transplant donors,many of the patients could not receive allo-HSCT,so how to prolong the relapse-free survival of these patients remains a challenge.Platzbecker et al treated MRD-positive patients with azacytidine(AZA),and found pre-emptive therapy with AZA can prevent or substantially delay hematological relapse in MRD-positive patients with MDS(myelodysplastic syndrome)or AML who are at a high risk of relapse.